Paul Richardson
MD
Clinical Program Leader and Director of Clinical Research
👥Biography 个人简介
Paul Richardson at Dana-Farber has been at the forefront of multiple myeloma drug development for over two decades. He has been a principal investigator in pivotal trials of bortezomib, lenalidomide, carfilzomib, pomalidomide, and many other novel agents that have transformed myeloma survival. His work on the development and optimal use of proteasome inhibitors and immunomodulatory drugs has shaped modern myeloma treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Paul Richardson 的研究动态
Follow Paul Richardson's research updates
留下邮箱，当我们发布与 Paul Richardson（Dana-Farber Cancer Institute / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment